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Abstract
Dystrophinopathy is a group of inherited phenotypes arising from pathogenic variants in
DMD. We evaluated the clinical and genetic characteristics of Korean patients with geneti-
cally confirmed dystrophinopathy. We retrospectively reviewed medical records (January
2004-September 2020) from the myopathy database maintained at the study hospital and
found 227 patients from 218 unrelated families with dystrophinopathy. Clinical phenotypes
included 120 (53%) Duchenne muscular dystrophy (DMD) cases, 20 (9%) intermediate phe-
notype muscular dystrophy (IMD) cases, 65 (29%) Becker muscular dystrophy (BMD)
cases, 18 (8%) undetermined phenotypes, and 4 (2%) symptomatic carriers. The median
ages at symptom onset and diagnosis were 5.0 years (interquartile range [IQR]: 3.8–8.0)
and 12.0 years (IQR: 7.0–21.0), respectively. Total manual muscle test (MMT) scores
decreased annually in patients with DMD, IMD, and BMD. Overall, when age increased by 1
year, total MMT scores decreased on average by -1.978, -1.681, and -1.303 in patients with
DMD (p<0.001), IMD (p<0.001), and BMD (p<0.001), respectively. Exonic deletion and
duplication were reported in 147 (67%) and 31 (14%) of the 218 unrelated probands, respec-
tively. A total of 37 different small sequence variants were found in 40 (18%) of the 218 pro-
bands. The reading frame rule was applicable to 142 (94%) of the 151 probands. The
present results highlight the long-term natural history and genetic spectrum of dystrophino-
pathy in a large-scale Korean cohort.
Introduction
Dystrophinopathy is a group of inherited phenotypes arising from pathogenic variants in
DMD [1, 2]. DMD is one of the largest human genes, comprising 79 exons and 7 promoters,
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with more than 2.5 million base pairs on chromosome Xp21.2 [3–5]. More than 7,000 different
variants in DMD have been reported to date (https://databases.lovd.nl/shared/genes/DMD).
The most common changes in DMD are exonic deletions, accounting for 69% of all dystrophin
mutations. Exonic duplications occur in approximately 11% of patients; the remaining 20%
are small sequence variants [6].
Dystrophinopathy is the most common type of muscular dystrophy in children, with a
prevalence of 21.2/100,000 in school-aged boys [7]. It is characterized by progressive muscle
degeneration and weakness. The clinical spectrum of dystrophinopathy is highly variable, pre-
senting as severe Duchenne muscular dystrophy (DMD), milder Becker muscular dystrophy
(BMD), X-linked dilated cardiomyopathy, and symptomatic female carriers: these clinical phe-
notypes appear to be related to the amount of dystrophin in skeletal muscle [8, 9]. Patients
with dystrophinopathy typically experience muscle weakness, along with cardiac, respiratory,
and orthopedic complications of varying degrees. Currently, there are no curative therapies
for dystrophinopathy. However, multidisciplinary care planning, including corticosteroids,
cardiac medications, orthopedic surgery, rehabilitation, and assisted ventilation, has been
found to improve quality of life and clinical outcomes, delaying death in patients with DMD
into their 30s or 40s [10, 11].
Recently, various therapies based on molecular mechanisms, including gene therapy, cell
therapy, read-through drugs, and antisense oligonucleotides for exon-skipping, have been
studied and subjected to clinical trials: of these, four antisense oligonucleotide drugs (eteplir-
sen, golodirsen, viltolarsen, and casimersen) have been approved by the United States Food
and Drug Administration for use in treating dystrophinopathy [12–15]. As such, genetic diag-
nosis of dystrophinopathy is becoming increasingly important. However, there are few studies
on the pathological and genetic characteristics of dystrophinopathy in Korea [16–18].
To evaluate genotype-phenotype correlations in dystrophinopathy, we investigated the
genetic spectrum and changes in clinical and laboratory findings with disease progression in
Korean patients with genetically confirmed dystrophinopathy.
Materials and methods
Study participants
The present study hospital is one of the largest myology centers in Korea, and our database
contains information on 2,331 unrelated patients with myopathy. We reviewed medical rec-
ords from January 2004 to September 2020 from the myopathy database and identified 227
patients from 218 unrelated families with dystrophinopathy. This research protocol was
approved by the institutional review board of Gangnam Severance Hospital, Korea (IRB No:
3-2020-0127). The need for written informed consent was waived by the board because this
was a retrospective study.
Phenotype and laboratory assessment
We analyzed the clinical spectrum of patients with dystrophinopathy using their medical rec-
ords, which included information on age at symptom onset, sex, family history, motor weak-
ness, presence of scoliosis, loss of ambulation, respiratory discomfort, dilated cardiomyopathy,
and use of mechanical ventilation. Five subgroups were defined, including DMD, BMD, inter-
mediate phenotype muscular dystrophy (IMD), undetermined phenotype (UD) (patients who
were ambulatory on medical records, but had no records after the age of 12 years) and symp-
tomatic carriers (females with muscle weakness of any severity). DMD, BMD, and intermedi-
ate phenotype muscular dystrophy (IMD) were defined according to age at loss of ambulation
(DMD <13 years, BMD�16 years, and 13 years� IMD <16 years) in accordance with
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established diagnostic criteria [19]. Motor weakness in individual movements was assessed
using manual muscle testing (MMT) scores (0, 1, 2, 3-, 3, 3+, 4-, 4, 4+, 5-, and 5). Next, MMT
scores were converted to an 11-point scale from 0 to 10. A total MMT score was calculated as
the sum of 10 strength values, which included the strength values of shoulder abduction, elbow
extension, elbow flexion, wrist extension, wrist flexion, hip flexion, knee extension, knee flex-
ion, ankle dorsiflexion, and ankle plantarflexion. The results of prior creatine kinase (CK),
echocardiography studies, and muscle biopsies were extracted from the medical records in
227, 162, and 43 patients, respectively.
Genetic spectrum
Among the 218 unrelated probands, 178 with exonic deletions or duplications were diagnosed
with multiplex ligation-dependent probe amplification (MLPA). The remaining 40 with small
sequence variants were genetically confirmed by targeted sequencing or whole-exome
sequencing. All identified variants were classified into benign, likely benign, uncertain signifi-
cance, pathogenic, or likely pathogenic variants, according to the guidelines of the American
College of Medical Genetics and Genomics [20]. The numbering for the pathogenic variants of
DMD was based on the cDNA sequence (accession: NM_004006.2). Next, we checked the
reading frame rule in 151 probands with exonic deletion or duplication using the LOVD
exonic deletions/duplications reading–frame checker (https://www.dmd.nl/). The reading
frame rule was not evaluated in 27 unrelated probands with exonic deletion or duplication for
the following reasons: (1) 16 probands had UD due to incomplete clinical data, (2) probands
had exonic duplication affecting two regions, (3) 3 probands were symptomatic carriers, (4) 2
probands had exonic deletions including a translation initiation site, and (5) 2 probands had
exonic deletions and duplications including the translation termination site.
Statistical analysis
Descriptive statistics of the clinical spectrum of patients are presented as frequencies and per-
centages for categorical variables and as means and standard deviations for continuous vari-
ables. To compare the degree of muscle weakness and serum levels of CK between groups over
time, time effects, group effects, and their interactions were included in a linear mixed model.
A first-order autoregressive covariance structure was considered such that the larger the inter-
val between time points of repeatedly measured data, the less of a correlation there was. All sta-
tistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA). The
significance level for the statistical analyses was set at P<0.05.
Results
Clinical spectrum
Table 1 and S1 Table summarize the clinical spectrum data of 227 Korean patients from 218
unrelated families with dystrophinopathy. There were 223 males (98%) and 4 females (2%).
Clinical phenotypes included 120 (53%) DMD, 20 (9%) IMD, 65 (29%) BMD, 18 (8%) UD,
and 4 (2%) symptomatic carrier cases. A family history was positive in 70 (31%) patients. The
median ages at symptom onset, diagnosis, and last examination were 5.0 (interquartile range
[IQR]: 3.8–8.0), 12.0 (IQR: 7.0–21.0), and 23.0 (IQR: 17.0–31.0) years, respectively. The
median follow-up period was 9 (IQR:3.0–15.0) years. Muscle biopsies were performed in 43
(19%) of the 227 patients. Among them, analysis of nine samples indicated end-stage muscle
disease. The remaining 34 muscle samples showed many degenerative/regenerative muscle
fibers, infiltration of inflammatory cells, and increased endomysial fibrosis.
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Immunohistochemical analysis of the N-terminal, rod-domain, and C-terminal of dystrophin
protein showed a total loss of expression in 20 patients with DMD, IMD, or UD and patchy
and faint staining of sarcolemma in 14 patients with BMD.
Among all patients, 18 were classified as having UD phenotype. The results of muscle
biopsy were extracted from medical records in only one patient (ID16). Therein, immunohis-
tochemistry for the rod domain, C-terminus, and N-terminus of dystrophin protein showed a
total loss of expression. All four symptomatic carriers complained of asymmetric motor weak-
ness of the proximal leg muscles; however, they did not complain of cardiac, respiratory, or
orthopedic complications. Therefore, we only compared the clinical characteristics of patients
with DMD, IMD, and BMD. Total MMT scores decreased annually in patients with DMD,
IMD, and BMD (Fig 1). Overall, when age increased by 1 year, total MMT scores decreased on
average by -1.978, -1.681, and -1.303 in patients with DMD (p<0.001), IMD (p<0.001), and
BMD (p<0.001), respectively. The slope difference between DMD and BMD was 0.675; this
difference was significant (p<0.001). However, the slope was not significantly different
Table 1. Clinical characteristics of 227 Korean patients with dystrophinopathy.
Total patients DMD IMD BMD UD Symptomatic carrier
Number of patients 227 120 (53%) 20 (9%) 65 (29%) 18 (8%) 4 (2%)
Age at the symptom onset, year 5.0 [3.8–8.0] 5.0 [3.0–6.0] 5.5 [4.0–7.8] 10.0 [6.0–15.5] 4.0 [3.0–6.3] 17.0 [5.8–29.0]
Age at the diagnosis, year 12.0 [7.0–21.0] 9.0 [7.0–15.8] 12.0 [8.0–22.3] 20.0 [13.0–28.5] 5.5 [3.8–7.0] 33.5 [12.3–36.0]
Age at the last follow-up, year 23.0 [17.0–31.0] 22.5 [17.0–28.0] 30.5 [24.3–35.5] 27.0 [19.0–37.5] 7.0 [5.8–8.3] 33.5 [12.3–42.8]
Family history 71 (31%) 37 (31%) 6 (30%) 25 (38%)
Males 223 (98%) 120 (100%) 20 (100%) 65 (100%) 18 (100%) 0 (0%)
MMT-sum score at the last follow-
up
14.0 [22.0–61.0] 15.0 [12.3–22.0] 15.0 [12.5–19.5] 70.0 [39.5–90.0] 81.5 [64.0–100.0] 83.0 [37.8–90.0]
Scoliosis
Scoliosis 146 (64%) 109 (91%) 19 (95%) 15 (23%) 3 (17%) 0 (0%)
Scoliosis surgery 33 (15%) 31 (26%) 2 (10%) 0 (0%) 0 (0%) 0 (0%)
Age at scoliosis surgery 14.0 [13.0–17.0] 14.0 [13.0–17.0] 12.0 and 18.0 – – –
Loss of ambulation 154 (68%) 120 (100%) 20 (100%) 13 (20%) 0 (0%) 0 (0%)
Age at the loss of ambulation 11.0 [10.0–12.0] 10.0 [9.0–11.0] 13.5 [130–14.0] 19.0 [17.0–25.0] – –
Respiratory function
Respiratory discomfort 121 (53%) 93 (78%) 17 (85%) 11 (17%) 0 (0%) 0 (0%)
Number of patients with
ventilator use
111 (49%) 87 (72%) 16 (80%) 8 (12%) 0 (0%) 0 (0%)
Age at the start of mechanical
ventilation
21.0 [18.0–25.0] 20.0 [17.0–22.0] 26.0 [23.0–28.0] 37.5 [30.3–44.8] – –
Cardiac evaluation n = 162 n = 105 n = 20 n = 36 n = 1 n = 1
Number of patients with DCMP 77 (48%) 57 (54%) 8 (40%) 12 (33%) 0 (0%) 0(0%)
Age at the diagnosis of DCMP 23.0 [18.0–28.0] 21.0 [17.5–26.0] 27.5 [20.8–28.0] 34.0 [26.5–38.0] – –
Death until the last follow-up 7 (3%) 6 (5%) 1 (5%) 0 (0%) 0 (0%) 0 (0%)












DMD, Duchenne muscular dystrophy; BMD, Becker muscular dystrophy; IMD, intermediate phenotype muscular dystrophy; UD, undetermined phenotype; DCMP,
dilated cardiomyopathy; CK, creatine kinase; MMT, manual muscle test: the Medical Research Council 5-point scale for strength was converted to an 11-point scale (0,
1, 2, 3-, 3, 3+, 4-, 4, 4+, 5-, and 5). The observed MMT scores ranged from 0 to 10 for each movement assessed. The MMT-sum score was the sum of 10 strength values,
including those for shoulder abduction, elbow extension, elbow flexion, wrist extension, wrist flexion, hip flexion, knee extension, knee flexion, ankle dorsiflexion, and
ankle plantarflexion.
https://doi.org/10.1371/journal.pone.0255011.t001
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between DMD and IMD (p = 0.217) or between IMD and BMD (p = 0.150). Median serum
CK levels at the time of diagnosis and the last follow-up were 3,262 (IQR: 1,132–12,052) and
1,034 (IQR: 375–3,310), respectively. Average serum CK levels decreased at an annual rate in
patients with DMD, IMD, and BMD (Fig 2). When age increased by 1 year, serum CK levels
decreased on average by -633.497, -356.871, and -127.657 in patients with DMD (p<0.001),
IMD (p<0.001), and BMD (p = 0.039), respectively. This annual decrease in serum CK levels
was significantly steeper in patients with DMD than in patients with IMD (p = 0.003) and
BMD (p<0.001). The median ages at the last examination were 22.5 [IQR: 17.0–28.0], 30.5
[IQR: 24.3–35.5], and 27.0 [IQR:19.0–37.5] years in 120 patients with DMD, 20 patients with
IMD, and 65 patients with BMD, respectively. Scoliosis was significantly more frequent in
patients with DMD (109 patients, 91%) and IMD (19 patients, 95%) than in patients with
BMD (15 patients, 23%, p<0.001). Loss of ambulation was significantly more frequent in
patients with DMD (118 patients, 98%) and IMD (21 patients, 100%) than in patients with
BMD (14 patients, 21%, p<0.001). Mechanical ventilation use was also significantly more fre-
quent in patients with DMD (86 patients, 71%) and IMD (17 patients, 81%) than in patients
with BMD (8 patients, 12%, p<0.001).
Fig 1. Changes in manual muscle test sum scores with age: A spaghetti plot. Individual changes in patients with Duchenne muscular dystrophy
(DMD), intermediate phenotype muscular dystrophy (IMD), and Becker muscular dystrophy (BMD). Blue, red, and green colors indicate patients
with DMD, IMD, and BMD, respectively. �MMT, manual muscle test: the MMT for strength was converted to an 11-point scale (0, 1, 2, 3-, 3, 3+,
4-, 4, 4+, 5-, and 5). The observed MMT scores ranged from 0 to 10 for each movement assessed. The total MMT score represents the sum of 10
strength values, including those for shoulder abduction, elbow extension, elbow flexion, wrist extension, wrist flexion, hip flexion, knee extension,
knee flexion, ankle dorsiflexion, and ankle plantarflexion.
https://doi.org/10.1371/journal.pone.0255011.g001
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Genetic spectrum
Exonic deletions and duplications were recorded in 147 (67%) and 31 (14%) of the 218 unre-
lated probands, respectively. The most common genotype was a deletion of exons 45–47 in 17
(8%) probands, followed by deletion of exons 45–48 in 7 (3%) probands and deletion of exon
51 in 7 (3%) probands (Table 2). The frequencies of exonic deletions (93, 69%) in 134
Fig 2. Changes in mean serum creatine kinase (CK) levels with age. Blue, red, and green colors indicate patients with Duchenne muscular
dystrophy (DMD), intermediate phenotype muscular dystrophy (IMD), and Becker muscular dystrophy, respectively. The average annual decrease in
serum creatine kinase level was significantly steeper in patients with DMD than in patients with IMD (p = 0.003) and BMD (p<0.001). (A) Change in
mean serum CK level with age for ages 0–12 and (B) change in mean serum CK level with age for ages 12 and above.
https://doi.org/10.1371/journal.pone.0255011.g002
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probands with DMD or IMD were similar to those of exonic deletion (41, 65%) in 63 probands
with BMD. However, the frequency of small sequence variants (19, 14%) in 134 probands with
DMD or IMD was lower than that (14, 22%) in 63 probands with BMD. Exonic deletions start-
ing in the proximal hot spot (exons 2–20) and the distal hot spot (exons 45–55) accounted for
22 (14%) and 104 (72%) of the 147 regions, respectively (Fig 3A). Exonic deletions affecting
both regions were not found. Exonic duplications affecting the two regions were found in four
probands with DMD. Four patients with DMD (ID 139, ID 153, ID187, and ID 201) had dupli-
cations of exons 2–7 and 45–51, duplications of exons 5–37 and 50–59, duplications of exons
52–53 and 56–61, and duplications of exons 52–53 and 56–61, respectively (S1 Table). There-
fore, we found 35 regions of exonic duplications in 31 probands. Exonic duplication starting
in the distal hot spot (exons 45–55) and the proximal hot spot (exons 2–20) accounted for 22
(63%) and 7 (20%) of the five regions, respectively (Fig 3B). A total of 37 different small
sequence variants were found in 40 (18%) of the 218 unrelated probands. There were 16 differ-
ent nonsense variants in 18 (8.3%) unrelated probands, 10 splicing-site variants in 11 (5.0%),
nine frameshift variants in 9 (4.1%), one deep-intronic variant in 1 (0.5%), and one missense
variant in 1 (0.5%) (Fig 4). Among the sequence variants, four variants were novel (namely,
c.491delCinsTT, c.3374C>A, c.4171A>T, and c.8219_8228delACCTCCAAGG).
Exonic deletions rescuable through mono-exon skipping
The most common exon skips applicable to the largest number of patients were skipping of
exon 51 in 18 (13%) of 134 probands with exonic deletion, followed by skipping of exon 45 in
16 (12%), exon 53 in 13 (10%), exon 44 in 13 (10%), exon 43 in 7 (5%), exon 50 in 7 (5%), and
exon 53 in 7 (5%) probands.
Table 2. Relationship between common exonic deletion/duplication and clinical phenotypes in Korean patients with dystrophinopathy.
Exonic deletion/duplication Total DMD IMD BMD UD Symptomatic carrier Reading-frame
Deletion of exons 45–47 17 0 0 14 3 0 In-frame
Deletion of exons 45–48 7 0 0 7 0 0 In-frame
Deletion of exon 51 7 6 1 0 0 0 Out-of-frame
Deletion of exons 3–7 6 2 0 3 1 0 Out-of-frame
Deletion of exon 45 6 5 1 0 0 0 Out-of-frame
Deletion of exons 49–50 6 3 1 0 2 0 Out-of-frame
Deletion of exons 45–49 6 0 0 6 0 0 In-frame
Deletion of exons 45–50 5 4 0 0 1 0 Out-of-frame
Deletion of exons 46–47 5 5 0 0 0 0 Out-of-frame
Deletion of exons 46–48 5 4 0 0 0 1 Out-of-frame
Deletion of exon 44 4 3 0 0 1 0 Out-of-frame
Deletion of exons 45–52 4 3 1 0 0 0 Out-of-frame
Deletion of exons 45–55 4 0 0 13 1 0 In-frame
Deletion of exons 48–52 4 3 0 0 0 1 Out-of-frame
Deletion of exons 45–54 3 1 0 1 1 0 Out-of-frame
Deletion of exons 46–52 3 2 1 0 0 0 Out-of-frame
Deletion of exon 50 3 3 0 0 0 0 Out-of-frame
Deletion of exons 50–52 3 3 0 0 0 0 Out-of-frame
Duplication of exon 2 3 3 2 0 1 0 Out-of-frame
DMD, Duchenne muscular dystrophy, BMD, Becker muscular dystrophy, IMD, intermediate phenotype muscular dystrophy, UD, undetermined phenotype.
https://doi.org/10.1371/journal.pone.0255011.t002
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Genotype-phenotype correlations
We evaluated the reading frame rule in 151 probands with exonic deletions or duplications.
Among the 151 probands, 106 (70%) had out-of-frame variants, whereas 45 (30%) had in-frame
variants. The reading frame rule was applied to 142 (94%) probands. Among them, 102 (96%)
of 106 probands with out-of-frame variants had a severe phenotype (DMD or IMD), and 40
(89%) of the 45 probands with in-frame variants had a mild phenotype (BMD). Nine unrelated
probands did not follow the reading frame rule. Among the four probands with BMD and an
out-of-frame deletion, three patients had a deletion of exons 3–7 and one had a deletion of
exons 45–54. Four patients with DMD had in-frame deletion of exons 10–44, 49–51, and 56–67
and in-frame duplication of exons 30–49. One patient with IMD had in-frame duplication of
exons 3–18. Further, out-of-frame deletion of exons 3–7 was found in two patients with DMD
and three patients with BMD (Table 2). Among the sequence variants, nonsense variants were
frequently found in 13 (10%) of 134 probands with DMD or IMD, compared with 4 (7%) of 63
probands with BMD. However, splicing variants were frequently found in 6 (10%) of 63 pro-
bands with BMD, compared with 6 (4%) of 134 probands with DMD or IMD.
Fig 3. Distribution of large rearrangements in 178 probands with dystrophinopathy. Red (A) and blue (B) colors indicate exonic deletions and exonic duplications,
respectively.
https://doi.org/10.1371/journal.pone.0255011.g003
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Discussion
The present study outlines the clinical and genetic spectra of 227 Korean patients from 218
unrelated families with dystrophinopathy. All patients were genetically diagnosed with dystro-
phinopathy through MLPA or next-generation sequencing.
The clinical presentation of our patients included progressive skeletal muscle weakness, ele-
vated serum CK levels, scoliosis, dilated cardiomyopathy, and respiratory discomfort. Most
patients with DMD were non-ambulatory at the age of 10, used a mechanical ventilator at the
age of 20, and were diagnosed with dilated cardiomyopathy at the age of 21 years. Total MMT
scores and serum CK levels decreased more rapidly with age in patients with DMD than those
with IMD or BMD. These findings were compatible with those in previous reports [3, 21, 22].
Our study showed that the proportions of large deletions, large duplications, and small
sequence variants were 67%, 14%, and 18%, respectively. This is consistent with previous
research [6, 18, 23, 24]. Our study showed that there were exonic deletions and exonic duplica-
tions mainly in the distal and proximal hot spots, respectively. The small sequence variants
were evenly distributed throughout the entire gene. These results are also compatible with pre-
vious results [18, 19, 23, 25]. Further, we found that skipping of exons 51, 45, and 53 could be
beneficial to Korean patients with dystrophinopathy. These results indicate that currently
developed exon skipping therapies (eteplirsen, golodirsen, viltolarsen, and casimersen) can
help many Korean patients with DMD [12, 13].
Regarding the relationship between genotype and phenotype, the reading frame rule
showed 94% agreement with the DMD global database [6]. The most inconsistent variant of
the reading frame rule was the deletion of exons 3–7, which is an out-of-frame variant; how-
ever, it was found in only two patients with DMD and three patients with BMD. The
Fig 4. Small sequence variants in DMD in 40 probands with dystrophinopathy. Red, blue, pink, light blue, and green colors indicate splicing, frameshift, non-sense,
deep intron, and missense variants, respectively. Bold text indicates novel variants. Dots indicate the frequency of each variant.
https://doi.org/10.1371/journal.pone.0255011.g004
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relationship between this variant and BMD is well known [26]. However, the mechanisms of
other inconsistent large rearrangements of the reading frame rule are not clear.
This study has several limitations. First, it was a retrospective study based on medical rec-
ords. Therefore, we could not include various clinical scales, such as a 6-min walk and the
North Star Ambulatory Assessment. We could only analyze limited clinical scales, such as
MMT scores. Second, our study was not a multicenter cohort study. Third, this study only
included Korean patients. Fourth, we could not analyze the effects of steroids on patients with
dystrophinopathy in this study. The use of steroids prolongs the ambulatory phase of dystro-
phinopathy. Therefore, the lack of steroid information may result in errors in distinguishing
DMD from IMD and BMD. However, we could not confirm the exact drug history, including
steroids, because that most of patients had also been treated at other hospitals. We could only
estimate that about two-thirds of patients had been treated with steroids according to the expe-
rience of other myology centers in Korea [18].
The present results highlight the long-term natural history and the genetic spectrum of a
large-scale Korean cohort of patients with dystrophinopathy. We demonstrated that the phe-
notype-genotype relationship and skipping of exons 51, 45, and 53 could be utilized for the
management of Korean patients with dystrophinopathy. Our results provide insights for devel-
oping therapeutic drugs and designing clinical trials in Korean patients with
dystrophinopathy.
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